NASDAQ : PVLA
Palvella Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 151.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.18B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 22.29M | 15.76M | 5.94M | 3.08M | 4.16M |
| Research & Development | 35.46M | 22.84M | 8.15M | 8.79M | 13.88M |
| Operating Expenses | 57.74M | 38.60M | 14.10M | 11.87M | 18.04M |
| Operating Income | -57.74M | -38.60M | -14.10M | -11.87M | -18.04M |
| Interest Expense | -7.60M | -5.82M | -4.32M | -10.36M | |
| Interest & Investment Income | 4.19M | 2.59M | 642.00K | 6.26M | |
| Other Non Operating Income (Expenses) | -545.00K | 115.00K | -764.00K | 1.20M | -174.00K |
| EBT Excluding Unusual Items | -61.70M | -41.72M | -18.53M | -4.41M | -28.58M |
| Other Unusual Items | 1.10M | 23.10M | |||
| Pretax Income | -61.70M | -41.72M | -17.43M | 18.69M | -28.58M |
| Income Tax Expense | -1.03M | ||||
| Net Income | -61.70M | -41.72M | -17.43M | 18.69M | -27.55M |
| Preferred Dividends & Other Adjustments | 14.81M | ||||
| Net Income to Common | -61.70M | -41.72M | -17.43M | 3.88M | -27.55M |
| Shares Outstanding (Basic) | 12.60M | 11.25M | 2.23M | 1.77M | 5.72M |
| Shares Outstanding (Diluted) | 12.60M | 11.25M | 2.23M | 1.79M | 5.72M |
| EPS (Basic) | -4.90 | -3.71 | -7.83 | 2.19 | -4.82 |
| EPS (Diluted) | -4.90 | -3.71 | -7.83 | 2.17 | -4.82 |
| EBIT | -57.74M | -38.60M | -14.10M | -11.87M | -18.04M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 187.80M | 57.98M | 83.60M | 7.35M | 16.05M |
| Cash & Short-Term Investments | 250.58M | 57.98M | 83.60M | 7.35M | 16.05M |
| Accounts Receivable | 358.00K | ||||
| Other Receivables | 400.00K | 1.98M | |||
| Receivables | 400.00K | 2.34M | |||
| Prepaid Expenses | 2.04M | 1.00M | 2.30M | 198.00K | 471.00K |
| Total Current Assets | 253.03M | 58.99M | 88.23M | 7.55M | 16.52M |
| Property, Plant & Equipment | 482.00K | 572.00K | |||
| Total Assets | 253.51M | 59.56M | 88.23M | 7.55M | 16.52M |
| Accounts Payable | 6.79M | 4.59M | 4.59M | 936.00K | 3.18M |
| Accrued Expenses | 3.70M | 3.65M | 4.29M | 1.25M | 2.44M |
| Current Portion of Leases | 217.00K | 202.00K | |||
| Other Current Liabilities | 1.24M | 2.90M | 3.17M | 169.00K | 159.00K |
| Total Current Liabilities | 11.95M | 11.34M | 12.04M | 2.36M | 5.78M |
| Long-Term Debt | 22.11M | 17.76M | 11.94M | 8.05M | 32.42M |
| Long-Term Leases | 318.00K | 431.00K | |||
| Other Long-Term Liabilities | 2.27M | 2.04M | 1.65M | 1.01M | 1.50M |
| Total Liabilities | 36.64M | 31.58M | 25.63M | 11.43M | 39.70M |
| Common Stock | 14.00K | 12.00K | 11.00K | ||
| Additional Paid-In Capital | 389.85M | 163.34M | 156.33M | 1.82M | 1.22M |
| Retained Earnings | -173.09M | -135.45M | -93.73M | -76.30M | -94.99M |
| Comprehensive Income & Other | 89.00K | 83.00K | 3.00K | ||
| Total Common Equity | 216.87M | 27.98M | 62.61M | -74.48M | -93.78M |
| Shareholders' Equity | 216.87M | 27.98M | 62.61M | -3.88M | -23.17M |
| Total Liabilities & Equity | 253.51M | 59.56M | 88.23M | 7.55M | 16.52M |
| Total Debt | 22.64M | 18.39M | 11.94M | 8.05M | 32.42M |
| Net Cash (Debt) | 227.94M | 39.59M | 71.66M | -704.00K | -16.36M |
| Net Cash Per Share | 18.10 | 3.52 | 32.19 | -0.39 | -2.86 |
| Filing Date Shares Outstanding | 14.41M | 14.31M | 11.02M | 5.72M | 5.72M |
| Total Common Shares Outstanding | 14.40M | 12.38M | 11.01M | 5.72M | 5.72M |
| Working Capital | 241.08M | 47.64M | 76.20M | 5.19M | 10.74M |
| Book Value Per Share | 15.06 | 2.26 | 5.69 | -13.02 | -16.40 |
| Tangible Book Value | 216.87M | 27.98M | 62.61M | -74.48M | -93.78M |
| Tangible Book Value Per Share | 15.06 | 2.26 | 5.69 | -13.02 | -16.40 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -61.70M | -41.72M | -17.43M | 18.69M | -27.55M |
| Stock-Based Compensation | 12.40M | 6.40M | 830.00K | 603.00K | 427.00K |
| Other Operating Activities | 8.19M | 6.49M | 5.96M | -29.85M | 10.66M |
| Change in Accounts Receivable | 387.00K | 387.00K | |||
| Change in Accounts Payable | 2.22M | 1.26M | 2.24M | -2.25M | 1.98M |
| Change in Other Net Operating Assets | 2.31M | 2.17M | -2.43M | -904.00K | -359.00K |
| Operating Cash Flow | -36.51M | -25.01M | -10.84M | -13.70M | -14.84M |
| Long-Term Debt Issued | 18.43M | 5.00M | |||
| Net Debt Issued (Repaid) | 18.43M | 5.00M | |||
| Issuance of Common Stock | 232.58M | 763.00K | 60.00M | 34.00K | |
| Other Financing Activities | -16.38M | -1.42M | 8.65M | ||
| Financing Cash Flow | 216.20M | -660.00K | 87.09M | 5.00M | 9.57M |
| Foreign Exchange Rate Adjustments | 151.00K | 46.00K | 3.00K | ||
| Net Cash Flow | 117.37M | -25.62M | 76.25M | -8.70M | -5.27M |
| Levered Free Cash Flow | -25.45M | -18.63M | -5.43M | -9.96M | |
| Unlevered Free Cash Flow | -20.70M | -14.99M | -2.74M | -9.96M | |
| Change in Working Capital | 4.92M | 3.82M | -193.00K | -3.15M | 1.62M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 2.12B | 1.24B | 134.66M | ||
| Enterprise Value | 1.89B | 1.19B | 215.12M | ||
| Last Close Price | 146.15 | 104.67 | 12.00 | ||
| PB Ratio | 9.70 | 44.27 | 2.15 | ||
| P/TBV Ratio | 9.71 | 44.27 | 2.15 | ||
| Debt / Equity Ratio | 0.10 | 0.66 | 0.19 | -2.08 | -1.40 |
| Net Debt / Equity Ratio | -1.05 | -1.42 | -1.15 | -0.18 | -0.71 |
| Quick Ratio | 21.01 | 5.11 | 7.14 | 3.11 | 2.78 |
| Current Ratio | 21.18 | 5.20 | 7.33 | 3.20 | 2.86 |
| Return on Equity (ROE) | -46.62% | -92.10% | -59.37% | ||
| Return on Assets (ROA) | -22.05% | -32.65% | -18.39% | -61.63% | |
| Return on Capital Employed (ROCE) | -23.90% | -80.10% | -18.50% | -228.80% | -167.90% |
| Earnings Yield | -3.33% | -3.37% | -12.95% | ||
| Buyback Yield / Dilution | -83.69% | -405.46% | -24.08% | 68.63% |